Free Trial
NASDAQ:ALKS

Alkermes (ALKS) Stock Price, News & Analysis

Alkermes logo
$30.00 +0.60 (+2.04%)
Closing price 09/3/2025 04:00 PM Eastern
Extended Trading
$29.11 -0.89 (-2.97%)
As of 09/3/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Alkermes Stock (NASDAQ:ALKS)

Key Stats

Today's Range
$29.66
$31.69
50-Day Range
$26.13
$30.46
52-Week Range
$25.56
$36.45
Volume
3.09 million shs
Average Volume
1.24 million shs
Market Capitalization
$4.95 billion
P/E Ratio
14.42
Dividend Yield
N/A
Price Target
$41.31
Consensus Rating
Moderate Buy

Company Overview

Alkermes Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
97th Percentile Overall Score

ALKS MarketRank™: 

Alkermes scored higher than 97% of companies evaluated by MarketBeat, and ranked 47th out of 696 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Alkermes has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Alkermes' stock forecast and price target.
  • Earnings Growth

    Earnings for Alkermes are expected to grow by 4.58% in the coming year, from $1.31 to $1.37 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alkermes is 14.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 269.50.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alkermes is 14.42, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 82.37.

  • Price to Earnings Growth Ratio

    Alkermes has a PEG Ratio of 1.67. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Alkermes has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Alkermes' valuation and earnings.
  • Percentage of Shares Shorted

    8.37% of the outstanding shares of Alkermes have been sold short.
  • Short Interest Ratio / Days to Cover

    Alkermes has a short interest ratio ("days to cover") of 7.7.
  • Change versus previous month

    Short interest in Alkermes has recently decreased by 0.07%, indicating that investor sentiment is improving.
  • Dividend Yield

    Alkermes does not currently pay a dividend.

  • Dividend Growth

    Alkermes does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.37% of the outstanding shares of Alkermes have been sold short.
  • Short Interest Ratio / Days to Cover

    Alkermes has a short interest ratio ("days to cover") of 7.7.
  • Change versus previous month

    Short interest in Alkermes has recently decreased by 0.07%, indicating that investor sentiment is improving.
  • News Sentiment

    Alkermes has a news sentiment score of 1.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Alkermes this week, compared to 8 articles on an average week.
  • Search Interest

    Only 4 people have searched for ALKS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $210,143.00 in company stock.

  • Percentage Held by Insiders

    Only 4.40% of the stock of Alkermes is held by insiders.

  • Percentage Held by Institutions

    95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Alkermes' insider trading history.
Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALKS Stock News Headlines

Alkermes initiated with an Overweight at Wells Fargo
“Shadow Group” in Washington, DC Could Crash Market
New Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split the entire U.S. market in two on or before Sept 30, causing a crisis "many times worse than 2008."tc pixel
Zacks Research Predicts Alkermes' Q3 Earnings (NASDAQ:ALKS)
Piper Sandler Keeps Their Buy Rating on Alkermes (ALKS)
See More Headlines

ALKS Stock Analysis - Frequently Asked Questions

Alkermes' stock was trading at $28.76 at the beginning of 2025. Since then, ALKS shares have increased by 4.3% and is now trading at $30.00.

Alkermes plc (NASDAQ:ALKS) released its quarterly earnings results on Tuesday, July, 29th. The company reported $0.52 earnings per share for the quarter, beating analysts' consensus estimates of $0.42 by $0.10. Alkermes's revenue for the quarter was down 2.1% on a year-over-year basis.
Read the conference call transcript
.

Alkermes' Board of Directors authorized a share repurchase plan on Thursday, February 15th 2024, which allows the company to repurchase $400,000,000 in shares, according to EventVestor. This means that the company could buy up to 8.2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's management believes its stock is undervalued.

Alkermes subsidiaries include Rodin Therapeutics.

Top institutional shareholders of Alkermes include State Street Corp (4.97%), JPMorgan Chase & Co. (2.93%), Geode Capital Management LLC (2.44%) and American Century Companies Inc. (2.22%). Insiders that own company stock include Christian Todd Nichols, Craig C Hopkinson, Cato T Laurencin and Nancy Wysenski.
View institutional ownership trends
.

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alkermes investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
7/29/2025
Today
9/03/2025
Next Earnings (Estimated)
10/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALKS
CIK
1520262
Employees
1,800
Year Founded
1987

Price Target and Rating

High Price Target
$52.00
Low Price Target
$26.00
Potential Upside/Downside
+37.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.08
Trailing P/E Ratio
14.42
Forward P/E Ratio
22.90
P/E Growth
1.67
Net Income
$367.07 million
Net Margins
23.15%
Pretax Margin
27.27%
Return on Equity
24.86%
Return on Assets
17.14%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.23
Quick Ratio
2.85

Sales & Book Value

Annual Sales
$1.56 billion
Price / Sales
3.18
Cash Flow
$2.74 per share
Price / Cash Flow
10.93
Book Value
$9.84 per share
Price / Book
3.05

Miscellaneous

Outstanding Shares
165,080,000
Free Float
157,815,000
Market Cap
$4.95 billion
Optionable
Optionable
Beta
0.53

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:ALKS) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners